CAMBRIDGE, Mass.–(BUSINESS WIRE)–GV20 Therapeutics, a biopharmaceutical company using cutting-edge genomics and artificial intelligence approaches to discover next-generation cancer therapies, announced three key leadership appointments to accelerate its growth and transition to a phased company. clinical. Shirley Liu, Ph.D., pioneering cancer researcher and co-founder. was appointed Chief Executive Officer; former executive at Shape Pharmaceuticals and Tensha Therapeutics, Steven Landau, MD, became chief medical officer; and Genentech veteran Ying Gong, Ph.D. was named Chief Commercial Officer.
Shirley Liu is an innovative and prolific computational cancer biologist. Having served on the faculty of the Dana-Farber Cancer Institute and the Harvard TH Chan School of Public Health for nearly 20 years, she has made significant contributions to the understanding of gene regulation and drug response in the cancer. Dr. Liu and Ted Xiao, Ph.D., a former postdoctoral fellow at the Dana-Farber Cancer Institute and Harvard Medical School, co-founded GV20 Therapeutics in 2016 with the goal of applying high-throughput genomics and computational approaches to the discovery and development of new anti-cancer drugs. The company’s efforts have led to the identification of new targets and drug candidates, including its lead candidate, XBH25, a novel NK checkpoint inhibitor targeting solid tumors. GV20 plans to file an IND for XBH25 in the second half of 2022.
“We are delighted to welcome Steve and Ying and their expertise to the GV20 team,” said CEO Shirley Liu. “Both Ying and Steve bring extensive experience in developing innovative oncology pipelines and building high performing teams. That Ying and Steve have chosen to help lead GV20 at this crucial inflection point is a testament to the power of our drug discovery capabilities and the potential of our pipeline. With their leadership, we are excited to advance XBH25 to the clinic and discover more promising candidates quickly and at scale with our integrated genomics and AI platform STEAD. We are well positioned to bring next-generation immunotherapies to cancer patients. »
ABOUT SHIRLEY LIU, PH.D.
Shirley Liu, Ph.D., co-founded GV20 Therapeutics in 2016 and joined the company full-time as CEO in 2022. A highly cited cancer researcher, Dr. Liu was previously a professor of biostatistics and computational biology at Dana-Farber Cancer Institute and Harvard TH Chan School of Public Health, and co-director of the Center for Functional Cancer Epigenetics at Dana-Farber. With over 250 peer-reviewed publications, his research has refined the understanding of hormone receptor therapies, epigenetic inhibitors, gamma-secretase inhibitors, receptor tyrosine kinase inhibitors, and immune checkpoint inhibitors. in different cancers. She is a member of the International Society of Computational Biology (ISCB), the American Institute for Medical and Biological Engineering (AIMBE) and was a researcher at the Breast Cancer Research Foundation (2017-2021). Liu is the recipient of the Sloan Research Fellowship (2008), the Endocrine Society’s Weitzman Outstanding Early Career Investigator Award (2016), the ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences. life (2020). Dr. Liu obtained his Ph.D. in Biomedical Informatics and Ph.D. Minor in Computer Science from Stanford.
ABOUT STEVEN LANDAU, MD
Steven Landau, MD, has more than 25 years of experience developing products for the treatment of cancers and inflammatory diseases, including the FDA-approved monoclonal antibody Entyvio®. He previously served as a medical director at oncology-focused companies including Shape Pharmaceuticals and Tensha Therapeutics. Dr. Landau has also supported product development at OraVax, LeukoSite, Millennium Pharmaceuticals and Praecis Pharmaceuticals. Dr. Landau received his MD from Case Western Reserve University and completed postgraduate training at Beth Israel Hospital and Brigham and Women’s Hospital in Boston.
ABOUT YING GONG, PH.D.
Ying Gong, Ph.D., is an experienced strategist, drug developer, and team leader. Most recently, she served as Project Team Leader for Oncology at Genentech, where she led drug development programs and commercial development projects from late stage research to proof of concept. clinical. Dr. Gong also served as Senior Director of Strategy and Portfolio Planning, shaping Genentech’s cutting-edge R&D strategy. Previously, she held roles in medical affairs, market access, global product strategy and market planning at Genentech and Roche, and worked on a wide range of projects including new indication launches. by Perjeta.® and Avastin®. She began her career as a management consultant at Bain & Company. Dr. Gong earned a Ph.D. in Biochemistry and Molecular Biophysics from the California Institute of Technology and a Masters in Molecular Genetics from Smith College.
ABOUT GV20 THERAPEUTIC
GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. The company closed a Series B funding led by Coatue Management in October 2021. GV20 uses high-throughput functional genomics and artificial intelligence to identify novel cancer immunologic drug targets and therapeutic antibodies. The Company’s pipeline includes XBH25, a novel NK checkpoint inhibitor targeting solid tumors, which is currently progressing to the clinic. “GV20” refers to one of the most important acupuncture points for the human body, symbolizing the company’s mission to find and exploit vulnerabilities in cancer biology.